Vertex Pharmaceuticals Stock Analysis

Vertex Stock Analysis Notes

About 98.0% of the company outstanding shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.58. Vertex Pharmaceuticals recorded earning per share (EPS) of 14.22. The entity had not issued any dividends in recent years. The firm had 2:1 split on the 24th of August 2000. Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 00 people. For more information please call MD FASN at 617 341 6100 or visit https://www.vrtx.com.

Vertex Pharmaceuticals Investment Alerts

Vertex Largest EPS Surprises

View All Earnings Estimates

Vertex Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Vertex Stock Institutional Investors

Note, although Vertex Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Vertex Market Capitalization

The company currently falls under 'Mega-Cap' category with a current market capitalization of 120.73 B.

Vertex Profitablity

The company has Profit Margin (PM) of 0.31 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.4 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.4.

Management Efficiency

Vertex Pharmaceuticals has return on total asset (ROA) of 0.1204 % which means that it generated a profit of $0.1204 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2231 %, meaning that it created $0.2231 on every $100 dollars invested by stockholders. Vertex Pharmaceuticals' management efficiency ratios could be used to measure how well Vertex Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.02 in 2026. Return On Capital Employed is likely to drop to -0.01 in 2026. At this time, Vertex Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 15.6 B in 2026, whereas Return On Tangible Assets are likely to drop (0.02) in 2026.

Technical Drivers

As of the 11th of February 2026, Vertex Pharmaceuticals has the Coefficient Of Variation of 1040.03, risk adjusted performance of 0.0826, and Semi Deviation of 1.33. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vertex Pharmaceuticals, as well as the relationship between them.

Vertex Pharmaceuticals Price Movement Analysis

Vertex Pharmaceuticals Insider Trading Activities

Vertex Pharmaceuticals Outstanding Bonds

Vertex Pharmaceuticals Predictive Daily Indicators

Vertex Pharmaceuticals Corporate Filings

Vertex Pharmaceuticals Forecast Models

Vertex Pharmaceuticals' time-series forecasting models are one of many Vertex Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Vertex Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Vertex Pharmaceuticals Bond Ratings

Vertex Pharmaceuticals financial ratings play a critical role in determining how much Vertex Pharmaceuticals have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Vertex Pharmaceuticals' borrowing costs.

Vertex Pharmaceuticals Debt to Cash Allocation

Vertex Pharmaceuticals currently holds 1.75 B in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. Vertex Pharmaceuticals has a current ratio of 4.61, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Vertex Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Vertex Pharmaceuticals Total Assets Over Time

Vertex Pharmaceuticals Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Vertex Pharmaceuticals uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Vertex Pharmaceuticals Debt Ratio

8.48

It appears most of the Vertex Pharmaceuticals' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Vertex Pharmaceuticals' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Vertex Pharmaceuticals, which in turn will lower the firm's financial flexibility.

Vertex Pharmaceuticals Corporate Bonds Issued

Vertex Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Vertex Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Vertex shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Vertex Pharmaceuticals. By using and applying Vertex Stock analysis, traders can create a robust methodology for identifying Vertex entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Vertex analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Vertex analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Vertex Pharmaceuticals stock analysis indicators help investors evaluate how Vertex Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Vertex Pharmaceuticals shares will generate the highest return on investment. By understating and applying Vertex Pharmaceuticals stock analysis, traders can identify Vertex Pharmaceuticals position entry and exit signals to maximize returns.

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.